ARS Pharmaceuticals Inc

SPRY is in a confirmed Stage 4 decline with medium-term bearish bias reinforced by an active Support Failure pattern. Price remains below declining 9-, 21-, and 50-period EMAs, with rallies consistently rejected. No mean-reversion eligibility is present, and speculative execution favors an immediate Sell Now into resistance near the broken support cluster.

• ↑Q2 2026 revenue of $33.7M topped consensus by 7.5% on neffy demand
• ↑Neffy holds 5% US epinephrine share with 16,000 unique prescribers
• ↓Q2 net loss of $62.3M (-$0.63/share) missed estimates by 31%